Selpercatinib

Active Ingredient: Selpercatinib
Form: Oral tablet
Brand Name: Retevmo
Generic Name: Selpacta
Generic Manufacturer: Ziska Pharmaceuticals

Indications:
Retevmo is indicated for the treatment of:

• Metastatic RET fusion–positive non-small cell lung cancer (NSCLC)

• Advanced or metastatic RET mutation–positive or RET fusion–positive thyroid cancer in patients aged 12 and older who require systemic therapy

Dosage and Administration:

• Patients weighing <50 kg: 120 mg orally per day (divided into two doses)

• Patients weighing ≥50 kg: 160 mg orally per day (divided into two doses)
  If a dose is missed by more than 6 hours, skip the missed dose. Dosage adjustments may be required when taken with antacids or other interacting medications.

Common Side Effects:
Elevated liver enzymes, hyperglycemia, decreased white blood cells and serum albumin, hypocalcemia, dry mouth, diarrhea, renal impairment, hypertension, fatigue, peripheral edema, thrombocytopenia, hypercholesterolemia, rash, and hyponatremia.

Frequently Asked Questions

Q: What is the relationship between Retevmo and Selpercatinib?
A: Retevmo is the brand name registered by the original manufacturer. Selpercatinib is its active ingredient.

Q: Is the Retevmo sold by Mediva Rx the original brand-name drug?
A: No. Mediva Rx offers a high-quality generic version manufactured by one of Bangladesh’s top 10 pharmaceutical companies. It contains the same active ingredient and therapeutic effect as the original, and is tested and approved by the Directorate General of Drug Administration (DGDA).

Q: Is the manufacturer of the Retevmo generic version reliable?
A: Yes. We work with Ziska Pharmaceuticals, a leading pharmaceutical company in Bangladesh with its own R&D, production, and quality control facilities. They are certified to meet international Good Manufacturing Practice (GMP) standards. You can purchase with confidence.

Q: What does Retevmo target and who is it for?
A: Retevmo specifically targets RET gene alterations. It is approved for RET fusion–positive NSCLC and certain RET-altered thyroid cancers. If your condition does not involve RET alterations, please consult our “Targeted Therapy Guide for Lung Adenocarcinoma” to explore other options.

Disclaimer:
This information is for reference only. Treatment decisions should always be made in consultation with your physician and based on the official medication guide and the latest clinical research.

Drug Instructions (Package Insert):
Download Link